Massachusetts-based Vertex Pharmaceuticals (NASDAQ: VRTX) and Swiss Crisper Therapeutics (NASDAQ: CRSP) have announced the designation…
Gilead JAK1 inhibitor Filgotinib 200 mg was shown to more effectively induce and maintain ulcerative colitis remission than a placebo.
BioCryst Pharmaceuticals (NASDAQ:BCRX) has iniated a phase 1 trial of the anti-viral Galidesivir in Brazil with funding from the NIAID.
Altimmune will develop the vaccine, AdCOVID, with University of Alabama at Birmingham, UAB, scientists to prepare for Phase 1 trials in Q3.
NantKwest and ImmunityBio will initiate a phase 2 trial of NK cells and IL-15 agonist N-803 for metastatic pancreatic cancer in June 2020.
Heat Biologics is finalizing completion of their COVID-19 vaccine and plans to initiate pre-clinical testing and apply for funding in Q2.
COVID-19 vaccine mRNA-1273 demonstrated safety and immunogenicity in a phase 1 trial. Moderna expects a phase 3 trial to start in July 2020.